Two Sigma Advisers’s Matinas BioPharma MTNB Stock Holding History

Two Sigma Advisers’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-406	Closed	-$236K	–	2598
2021 Q2	$236K	Sell	406 -298	-42%	-$192K	﹤0.01%	2224
2021 Q1	$554K	Sell	704 -71	-9%	-$71.4K	﹤0.01%	1971
2020 Q4	$790K	Sell	775 -554	-42%	-$385K	﹤0.01%	1677
2020 Q3	$764K	Buy	1,329 +802	+152%	+$478K	﹤0.01%	1621
2020 Q2	$305K	Buy	527 +391	+288%	+$225K	﹤0.01%	2113
2020 Q1	$61K	Buy	+136	New	+$123K	﹤0.01%	2362

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Courage Capital Management Nashville, Tennessee $67.3M AUM 9.93% 1-Year Est. Return

Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

GSA Capital Partners London, United Kingdom $1.59B AUM 39.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Two Sigma Advisers's MTNB Position: Q3 2021 in Review

Two Sigma Advisers sold out of Matinas BioPharma (MTNB) in Q3 2021, closing a stake of 406 shares — an estimated $236K sold.

Two Sigma Advisers first reported a position in MTNB in Q1 2020 and held it in 6 quarters. The position peaked at $790K in Q4 2020. 67 funds tracked by Wall St. Rank hold MTNB as of Q3 2021.

Two Sigma Advisers reported no remaining Matinas BioPharma position as of Q3 2021 after selling out during the quarter.
Two Sigma Advisers sold 406 Matinas BioPharma shares in Q3 2021, an estimated $236K.
Two Sigma Advisers first reported a position in Matinas BioPharma in Q1 2020 and held it in 6 quarters.
Two Sigma Advisers's Matinas BioPharma position peaked at $790K in Q4 2020.
67 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2021.

Based on Two Sigma Advisers's 13F filing for Q3 2021, filed 15 Nov 2021.